NC
SPRY icon

nVerses Capital’s ARS Pharmaceuticals SPRY Stock Holding History

nVerses Capital’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2,100
Closed -$30.4K – 766
2024
Q3 		$30.4K Buy
+2,100
New +$25K 0.01% 741

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

nVerses Capital's SPRY Position: Q4 2024 in Review

nVerses Capital sold out of ARS Pharmaceuticals (SPRY) in Q4 2024, closing a stake of 2,100 shares — an estimated $30.4K sold.

nVerses Capital first reported a position in SPRY in Q3 2024 and held it in 1 quarter. The position peaked at $30.4K in Q3 2024. 165 funds tracked by Wall St. Rank hold SPRY as of Q4 2024.

  • nVerses Capital reported no remaining ARS Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • nVerses Capital sold 2,100 ARS Pharmaceuticals shares in Q4 2024, an estimated $30.4K.
  • nVerses Capital first reported a position in ARS Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • nVerses Capital's ARS Pharmaceuticals position peaked at $30.4K in Q3 2024.
  • 165 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q4 2024.

Based on nVerses Capital's 13F filing for Q4 2024.